<DOC>
	<DOCNO>NCT00225303</DOCNO>
	<brief_summary>The purpose study determinate effectiveness , safety tolerability ( well body accepts drug ) investigational Non-Nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) call TMC125 .</brief_summary>
	<brief_title>TMC125-C227 : A Phase II Randomized , Active-Controlled , Open Label Trial Investigate Efficacy Tolerability TMC125 HIV-1 Infected Subjects , Who Are PI-Naive With Documented Genotypic Evidence NNRTI Resistance From Previous NNRTI Use</brief_title>
	<detailed_description>Patients previously receive first HIV NNRTI contain regimen receive NNRTI contain treatment prevention mother child transmission ( MTCT ) , never use protease inhibitor ( PI ) may eligible participate . TMC125 ( 800 mg b.i.d . old formulation formulation switch , 200 mg b.i.d . new formulation ) study versus active control ( investigator select PI ) . All patient receive underlying therapy contain 2 investigator select NRTIs . 300 patient enrolled Argentina , Brazil , Mexico , Peru , Chile , Costa Rica , Russia , South-Africa , Spain , Thailand , UK , USA , Thailand , India Malaysia . The duration study 48 week optional extension patient TMC125 treatment group virologic failure commercial availability drug . TMC125 800mg twice daily old formulation ; formulation switch , TMC125 200mg twice daily new formulation . The initial duration 48 week optional extension patient TMC125 treatment group virologic failure commercially availability .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Male female , age 18 year older Documented HIV1 infection Stable NNRTIcontaining ART ( minimum 12 week ) screen OR treatment interruption ( minimum 4 week ) screening OR receive NNRTI alone combination ARVs prevention MTCT Plasma viral load screening 1000 HIV1 RNA copies/ml Prior NNRTIexperience document genotypic evidence resistance currently available NNRTIs ( define least one NNRTIassociated mutation per IASUSA Drug resistance Mutation guideline ) Sensitive 2 NRTIs use underlaying ART Subject give informed consent Previous treatment Protease Inhibitors Presence currently active AIDS defining illness except stable cutaneous Kaposi 's Sarcoma Wasting syndrome due HIV infection Current past history alcohol and/or drug use , investigator 's opinion , would compromise subject 's safety compliance study protocol procedure Acute Hepatitis A , B C chronic hepatitis B C elevate LFTs &gt; 3 time ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>TMC125</keyword>
	<keyword>Non-Nucleoside reverse transcriptase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>TMC125-C227</keyword>
</DOC>